The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat ...

Novo Nordisk is developing the molecule for the treatment of obesity ... CagriSema, for example, combines semaglutide, the main pharmaceutical ingredient in the company’s approved obesity ...

On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug leveraging the foundational semaglutide molecule used in Wegovy ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Semaglutide sells for $997 a month when branded under Ozempic and $1,349 a month for Wegovy. The haircut to Ozempic may have a spillover effect on competitor drugs from Eli Lilly — Mounjaro and ...

Novo Nordisk announced that a higher dose of semaglutide (Wegovy ... 15.1%). Also, the molecule has officially been selected to be part of Medicare negotiation starting in 2027.